Erratum: Germ cell tumors with malignant somatic transformation: A mayo clinic experience (Oncology Research and Treatment (2019) 42 (95-100) DOI: 10.1159/000495802)

C. J. Scheckel, H. E. Kosiorek, R. Butterfield, Thai H Ho, T. Hilal

Research output: Contribution to journalComment/debate

Abstract

The affiliations were incorrect. The correct affiliations are as follows: Caleb J. Scheckela, Heidi E. Kosiorekb, Richard Butterfieldb, Thai H. Hoc, Talal Hilalc aDepartment of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA; bDepartment of Health Sciences Research, BioStatistics, Mayo Clinic, Phoenix, AZ, USA; cDivision of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA In the Abstract, wrong figures are given in the Results section. The correct Results section is as follows: Results: We identified 24 cases of GCTs with MST; the MST was adenocarcinoma in 50% and sarcoma in 50%. Median age at diagnosis was 27. Alpha-fetoprotein and beta-human chorionic gonadotropin were undetectable in 46%, both were elevated in 29%. The majority were advanced stage (71% stage III), and International Germ Cell Cancer Collaborative Group (IGCCCG) risk was classified as "good" in 58%. Median follow-up was 41 months (range 10-346 months). Median progression-free survival was 84 months (95% confidence interval (CI) 56-232), and median overall survival was 219 months (95% CI 165-not reported). Moreover, several figures in Patient Characteristics of the Results section were falsely given. The correct figures are as follows: Patient Characteristics The average age at diagnosis was 27 years (range 16-51 years) (Table 1). The types of MST were evenly distributed with 12 adenocarcinomas and 12 sarcomas, 5 of which were further subclassified as rhabdomyosarcoma. Primary tumor location was predominantly in the testes (21/24); a single case each arose from the mediastinum, pineal gland, and retroperitoneum (3/24). At the time of presentation, 4 patients had disease localized to the testes (stage I), 3 had disease metastasized to retroperitoneal lymph nodes (stage II), and the majority (17/24) of patients had stage III disease with metastatic locations including brain, neck, chest wall, lung, inferior vena cava, aorta, and bowel. IGCCCG risk classification identified most cases as "good risk" (14/24), and the rest as "intermediate risk" (4/24) and "poor risk" (6/24). Tumor marker analysis at diagnosis showed undetectable alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (β-hCG) in 46% (11/24), both were elevated in 29% (7/24), only AFP was elevated in 17% (4/24), and only β-hCG was elevated in 8% (2/24).

Original languageEnglish (US)
Number of pages1
JournalOncology Research and Treatment
Volume42
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Germ Cell and Embryonal Neoplasms
alpha-Fetoproteins
Research
Chorionic Gonadotropin
Sarcoma
Testis
Adenocarcinoma
Biostatistics
Confidence Intervals
Therapeutics
Pineal Gland
Rhabdomyosarcoma
Mediastinum
Inferior Vena Cava
Thoracic Wall
Hematology
Tumor Biomarkers
Internal Medicine
Disease-Free Survival
Aorta

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Erratum : Germ cell tumors with malignant somatic transformation: A mayo clinic experience (Oncology Research and Treatment (2019) 42 (95-100) DOI: 10.1159/000495802). / Scheckel, C. J.; Kosiorek, H. E.; Butterfield, R.; Ho, Thai H; Hilal, T.

In: Oncology Research and Treatment, Vol. 42, No. 6, 01.06.2019.

Research output: Contribution to journalComment/debate

@article{21a5358f3d584be4b48e514d8ff4879f,
title = "Erratum: Germ cell tumors with malignant somatic transformation: A mayo clinic experience (Oncology Research and Treatment (2019) 42 (95-100) DOI: 10.1159/000495802)",
abstract = "The affiliations were incorrect. The correct affiliations are as follows: Caleb J. Scheckela, Heidi E. Kosiorekb, Richard Butterfieldb, Thai H. Hoc, Talal Hilalc aDepartment of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA; bDepartment of Health Sciences Research, BioStatistics, Mayo Clinic, Phoenix, AZ, USA; cDivision of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA In the Abstract, wrong figures are given in the Results section. The correct Results section is as follows: Results: We identified 24 cases of GCTs with MST; the MST was adenocarcinoma in 50{\%} and sarcoma in 50{\%}. Median age at diagnosis was 27. Alpha-fetoprotein and beta-human chorionic gonadotropin were undetectable in 46{\%}, both were elevated in 29{\%}. The majority were advanced stage (71{\%} stage III), and International Germ Cell Cancer Collaborative Group (IGCCCG) risk was classified as {"}good{"} in 58{\%}. Median follow-up was 41 months (range 10-346 months). Median progression-free survival was 84 months (95{\%} confidence interval (CI) 56-232), and median overall survival was 219 months (95{\%} CI 165-not reported). Moreover, several figures in Patient Characteristics of the Results section were falsely given. The correct figures are as follows: Patient Characteristics The average age at diagnosis was 27 years (range 16-51 years) (Table 1). The types of MST were evenly distributed with 12 adenocarcinomas and 12 sarcomas, 5 of which were further subclassified as rhabdomyosarcoma. Primary tumor location was predominantly in the testes (21/24); a single case each arose from the mediastinum, pineal gland, and retroperitoneum (3/24). At the time of presentation, 4 patients had disease localized to the testes (stage I), 3 had disease metastasized to retroperitoneal lymph nodes (stage II), and the majority (17/24) of patients had stage III disease with metastatic locations including brain, neck, chest wall, lung, inferior vena cava, aorta, and bowel. IGCCCG risk classification identified most cases as {"}good risk{"} (14/24), and the rest as {"}intermediate risk{"} (4/24) and {"}poor risk{"} (6/24). Tumor marker analysis at diagnosis showed undetectable alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (β-hCG) in 46{\%} (11/24), both were elevated in 29{\%} (7/24), only AFP was elevated in 17{\%} (4/24), and only β-hCG was elevated in 8{\%} (2/24).",
author = "Scheckel, {C. J.} and Kosiorek, {H. E.} and R. Butterfield and Ho, {Thai H} and T. Hilal",
year = "2019",
month = "6",
day = "1",
doi = "10.1159/000499397",
language = "English (US)",
volume = "42",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Erratum

T2 - Germ cell tumors with malignant somatic transformation: A mayo clinic experience (Oncology Research and Treatment (2019) 42 (95-100) DOI: 10.1159/000495802)

AU - Scheckel, C. J.

AU - Kosiorek, H. E.

AU - Butterfield, R.

AU - Ho, Thai H

AU - Hilal, T.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The affiliations were incorrect. The correct affiliations are as follows: Caleb J. Scheckela, Heidi E. Kosiorekb, Richard Butterfieldb, Thai H. Hoc, Talal Hilalc aDepartment of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA; bDepartment of Health Sciences Research, BioStatistics, Mayo Clinic, Phoenix, AZ, USA; cDivision of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA In the Abstract, wrong figures are given in the Results section. The correct Results section is as follows: Results: We identified 24 cases of GCTs with MST; the MST was adenocarcinoma in 50% and sarcoma in 50%. Median age at diagnosis was 27. Alpha-fetoprotein and beta-human chorionic gonadotropin were undetectable in 46%, both were elevated in 29%. The majority were advanced stage (71% stage III), and International Germ Cell Cancer Collaborative Group (IGCCCG) risk was classified as "good" in 58%. Median follow-up was 41 months (range 10-346 months). Median progression-free survival was 84 months (95% confidence interval (CI) 56-232), and median overall survival was 219 months (95% CI 165-not reported). Moreover, several figures in Patient Characteristics of the Results section were falsely given. The correct figures are as follows: Patient Characteristics The average age at diagnosis was 27 years (range 16-51 years) (Table 1). The types of MST were evenly distributed with 12 adenocarcinomas and 12 sarcomas, 5 of which were further subclassified as rhabdomyosarcoma. Primary tumor location was predominantly in the testes (21/24); a single case each arose from the mediastinum, pineal gland, and retroperitoneum (3/24). At the time of presentation, 4 patients had disease localized to the testes (stage I), 3 had disease metastasized to retroperitoneal lymph nodes (stage II), and the majority (17/24) of patients had stage III disease with metastatic locations including brain, neck, chest wall, lung, inferior vena cava, aorta, and bowel. IGCCCG risk classification identified most cases as "good risk" (14/24), and the rest as "intermediate risk" (4/24) and "poor risk" (6/24). Tumor marker analysis at diagnosis showed undetectable alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (β-hCG) in 46% (11/24), both were elevated in 29% (7/24), only AFP was elevated in 17% (4/24), and only β-hCG was elevated in 8% (2/24).

AB - The affiliations were incorrect. The correct affiliations are as follows: Caleb J. Scheckela, Heidi E. Kosiorekb, Richard Butterfieldb, Thai H. Hoc, Talal Hilalc aDepartment of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA; bDepartment of Health Sciences Research, BioStatistics, Mayo Clinic, Phoenix, AZ, USA; cDivision of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA In the Abstract, wrong figures are given in the Results section. The correct Results section is as follows: Results: We identified 24 cases of GCTs with MST; the MST was adenocarcinoma in 50% and sarcoma in 50%. Median age at diagnosis was 27. Alpha-fetoprotein and beta-human chorionic gonadotropin were undetectable in 46%, both were elevated in 29%. The majority were advanced stage (71% stage III), and International Germ Cell Cancer Collaborative Group (IGCCCG) risk was classified as "good" in 58%. Median follow-up was 41 months (range 10-346 months). Median progression-free survival was 84 months (95% confidence interval (CI) 56-232), and median overall survival was 219 months (95% CI 165-not reported). Moreover, several figures in Patient Characteristics of the Results section were falsely given. The correct figures are as follows: Patient Characteristics The average age at diagnosis was 27 years (range 16-51 years) (Table 1). The types of MST were evenly distributed with 12 adenocarcinomas and 12 sarcomas, 5 of which were further subclassified as rhabdomyosarcoma. Primary tumor location was predominantly in the testes (21/24); a single case each arose from the mediastinum, pineal gland, and retroperitoneum (3/24). At the time of presentation, 4 patients had disease localized to the testes (stage I), 3 had disease metastasized to retroperitoneal lymph nodes (stage II), and the majority (17/24) of patients had stage III disease with metastatic locations including brain, neck, chest wall, lung, inferior vena cava, aorta, and bowel. IGCCCG risk classification identified most cases as "good risk" (14/24), and the rest as "intermediate risk" (4/24) and "poor risk" (6/24). Tumor marker analysis at diagnosis showed undetectable alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (β-hCG) in 46% (11/24), both were elevated in 29% (7/24), only AFP was elevated in 17% (4/24), and only β-hCG was elevated in 8% (2/24).

UR - http://www.scopus.com/inward/record.url?scp=85065616642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065616642&partnerID=8YFLogxK

U2 - 10.1159/000499397

DO - 10.1159/000499397

M3 - Comment/debate

C2 - 31238323

AN - SCOPUS:85065616642

VL - 42

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 6

ER -